©TheCanadian Journal ofUrology™: International Supplement, April 2014
46
Imaging approacheswith advancedprostate cancer: techniques and timing
pharmacodynamic potential. The development of an
accurate imagingbiomarker is fraughtwithdifficulties,
botheconomicandlogistic. Thereisincreasingnecessity,
however, for thedevelopmentof imaging tools that can
characterizethecancerphenotype,sinceimagingpermits
assessment of lesions throughout the body. Proper
application anddevelopment of the range of available
imagingmodalities and techniques will lead tomore
rapid identification and appropriate modification of
targeted therapies in thisprevalent diseasewithagrim
prognosis.
Disclosure
Dr. David Leung, Saravanan Krishnamoothy and
LawrenceSchwartzhavenopotentialconflictofinterest.
Dr.ChaitanyaDivgihasreceivedhonoraria fromBayer
AG andWilexAG.
References
1. Moore CM, Robertson NL, Arsanious N et al. Image-guided
prostate biopsy using magnetic resonance imaging-derived
targets: a systematic review.
EurUrol
2013;63(1):125-140.
2. D’AmicoAV,Moul J, Carroll PR, SunL, LubeckD, ChenMH.
Prostate specific antigen doubling time as a surrogate end
point for prostate cancer specific mortality following radical
prostatectomy or radiation therapy.
J Urol
2004;172(5 Pt 2):
S42-S46.
3. Perlmutter MA, Lepor H. Prostate-specific antigen doubling
time isareliablepredictorof imageablemetastases inmenwith
biochemical recurrenceafter radical retropubicprostatectomy.
Urology
2008;71(3):501-505.
4. BubendorfL,SchopferA,WagnerUetal.Metastaticpatternsof
prostate cancer: anautopsy studyof 1589patients.
HumPathol
2000;31(6):578-583.
5. ImbriacoM, LarsonSM,YeungHWet al.Anewparameter for
measuring metastatic bone involvement by prostate cancer:
thebone scan index.
ClinCancerRes
1998;4(7):1765-1772.
6. Dennis ER, Jia X, Mezheritskiy IS et al. Bone scan index:
a quantitative treatment response biomarker for castration-
resistant metastatic prostate cancer.
J Clin Oncol
2012;30(5):
519-524.
7. UlmertD,KabotehR, Fox JJ et al.Anovel automatedplatform
for quantifying the extent of skeletal tumour involvement in
prostatecancerpatientsusingthebonescan index.
EurUrol
2012;
62:78-84.
8. NationalOncologicPet Registry.Available fromURL: http://
29, 2013.
9. Even-SapirE,MetserU,Mishani Eet al. Thedetectionof bone
metastases in patients with high-risk prostate cancer: 99mtc-
mdpplanar bone scintigraphy, single- andmultifield-of-view
SPECT, 18F-fluoridepet, and18F-fluoridePET/CT.
JNuclMed
2006;47(2):287–297.
10. Iagaru A, Mittra E, Dick DW, Gambhir SS. Prospective
evaluation of (99m)TcMDP scintigraphy, (18)f NaF PET/CT,
and (18)FDGPET/CT fordetectionof skeletalmetastases.
Mol
ImagingBiol
2012;14(2):252-259.
11. Scher HI, Morris MJ, KellyWK et al. Prostate cancer clinical
trialendpoints:“RECIST”ingastepbackwards.
ClinCancerRes
2005;11(14):5223-5232.
12.Schöder H, Herrmann K, Gönen M et al. 2-[18F]fluoro-2-
deoxyglucosepositronemission tomography for thedetection
ofdisease inpatientswithprostate-specificantigenrelapseafter
radical prostatectomy.
ClinCancerRes
2005;11(13):4761-4769.
13.Morris MJ, Akhurst T, Larson SM et al. Fluorodeoxyglucose
positron emission tomography as an outcome measure for
castratemetastaticprostatecancer treatedwithantimicrotubule
chemotherapy.
ClinCancerRes
2005;11(9):3210-3216.
14.Tolvanen T, Yli-Kerttula T, Ujula T et al. Biodistribution and
radiationdosimetryof [(11)C]choline:acomparisonbetweenrat
andhumandata.
Eur JNuclMedMol Imaging
2010;37(5):874-883.
15.PicchioM,SpinapoliceEG,FallancaFetal. [11C]cholinePET/CT
detectionof bonemetastases inpatientswithPSAprogression
after primary treatment for prostate cancer: comparisonwith
bonescintigraphy.
Eur JNuclMedMol Imaging
2012;39(1):13-26.
16.U.S. Food and Drug Administration (FDA). Available from
URL:
PressAnnouncements/ucm319201.htm?source=govdelivery.
AccessedDecember 29, 2013.
17.Bauman G, Belhocine T, Kovacs M, Ward A, Beheshti M,
Rachinsky I. 18F-fluorocholine for prostate cancer imaging: a
systematic reviewof the literature.
ProstateCancerProstaticDis
2012;15(1):45-55.
18.Beheshti M, Vali R, Waldenberger P et al. Detection of bone
metastases inpatientswithprostatecancerby18Ffluorocholine
and18FfluoridePET-CT: a comparative study.
Eur JNuclMed
Mol Imaging
2008;35(10):1766-1774.
19.OyamaN,AkinoH,KanamaruHetal. 11c-acetatepet imaging
of prostate cancer.
JNuclMed
2002;43(2):181-186.
20.OyamaN,MillerTR,DehdashtiFetal.11C-acetatepet imaging
ofprostatecancer:detectionofrecurrentdiseaseatPSArelapse.
JNuclMed
2003;44(4):549–555.
21.Fricke E, Machtens S, Hofmann M et al. Positron emission
tomographywith11C-acetate and18F-FDG inprostate cancer
patients.
Eur JNuclMedMol Imaging
2003;30(4):607-611.
22.Yu EY, Muzi M, Hackenbracht JA et al. C11-acetate and F-18
FDG PET for men with prostate cancer bone metastases:
relativefindings and response to therapy.
ClinNuclMed
2011;
36(3):192-198.
23.MatthiesA,EzziddinS,UlrichEMetal.Imagingofprostatecancer
metastaseswith18f-fluoroacetateusingpet/ct.
Eur JNuclMed
Mol Imaging
2004;31(5):797.
24. JadvarH.Prostatecancer:PETwith18F-FDG,18F-or11C-acetate,
and18F- or 11C-choline.
JNuclMed
2011;52(1):81-89.
25.BrandesSJ,Katzenellenbogen JA.Fundamental considerations
in thedesignoffluorine-18 labeledprogestinsandandrogensas
imaging agents for receptor-positive tumors of the breast and
prostate.
Int JRadAppl InstrumB
1988;15(1):53-67.
26.Larson SM, Morris M, Gunther I et al. Tumor localization of
16beta-18F-fluoro-5-alpha-dihydrotestosteroneversus18F-FDG
inpatientswithprogressive,metastaticprostate cancer.
JNucl
Med
2004;45(3):366-373.
27.Dehdashti F, Picus J,Michalski JM et al. Positron tomographic
assessmentof androgen receptors inprostaticcarcinoma.
Eur J
NuclMedMol Imaging
2005;32(3):344-350.
28.ManyakMJ.Indium-111capromabpendetideinthemanagement
ofrecurrentprostatecancer.
ExpertRevAnticancerTher
2008;8(2):
175-181.
29.PucarD,SellaT,SchöderH.Theroleof imaging in thedetection
ofprostate cancer local recurrenceafter radiation therapyand
surgery.
CurrOpinUrol
2008;18(1):87-97.
